Summary

The global Vaginosis Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria.
United States market for Vaginosis Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Vaginosis Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Vaginosis Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Vaginosis Drug players cover Bayer, Pfizer, Sanofi, Piramal, Abbott, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Vaginosis Drug Industry Forecast” looks at past sales and reviews total world Vaginosis Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Vaginosis Drug sales for 2025 through 2031. With Vaginosis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaginosis Drug industry.
This Insight Report provides a comprehensive analysis of the global Vaginosis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaginosis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Vaginosis Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaginosis Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaginosis Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Vaginosis Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Rx
OTC
Segmentation by Application:
Hospital
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bayer
Pfizer
Sanofi
Piramal
Abbott
Galderma
Mission
Alkem
Xiuzheng
Teva
Perrigo
West-Ward
HPGC
Yunnan Baiyao
Starpharma
Novel
Edenvridge
Key Questions Addressed in this Report
What is the 10-year outlook for the global Vaginosis Drug market?
What factors are driving Vaginosis Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vaginosis Drug market opportunities vary by end market size?
How does Vaginosis Drug break out by Type, by Application?

ページTOPに戻る

List of Tables/Graphs

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Vaginosis Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Vaginosis Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Vaginosis Drug by Country/Region, 2020, 2024 & 2031
2.2 Vaginosis Drug Segment by Type
2.2.1 Rx
2.2.2 OTC
2.3 Vaginosis Drug Sales by Type
2.3.1 Global Vaginosis Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Vaginosis Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Vaginosis Drug Sale Price by Type (2020-2025)
2.4 Vaginosis Drug Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Other
2.5 Vaginosis Drug Sales by Application
2.5.1 Global Vaginosis Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Vaginosis Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Vaginosis Drug Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Vaginosis Drug Breakdown Data by Company
3.1.1 Global Vaginosis Drug Annual Sales by Company (2020-2025)
3.1.2 Global Vaginosis Drug Sales Market Share by Company (2020-2025)
3.2 Global Vaginosis Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Vaginosis Drug Revenue by Company (2020-2025)
3.2.2 Global Vaginosis Drug Revenue Market Share by Company (2020-2025)
3.3 Global Vaginosis Drug Sale Price by Company
3.4 Key Manufacturers Vaginosis Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaginosis Drug Product Location Distribution
3.4.2 Players Vaginosis Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Vaginosis Drug by Geographic Region
4.1 World Historic Vaginosis Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Vaginosis Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Vaginosis Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Vaginosis Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Vaginosis Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Vaginosis Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Vaginosis Drug Sales Growth
4.4 APAC Vaginosis Drug Sales Growth
4.5 Europe Vaginosis Drug Sales Growth
4.6 Middle East & Africa Vaginosis Drug Sales Growth
5 Americas
5.1 Americas Vaginosis Drug Sales by Country
5.1.1 Americas Vaginosis Drug Sales by Country (2020-2025)
5.1.2 Americas Vaginosis Drug Revenue by Country (2020-2025)
5.2 Americas Vaginosis Drug Sales by Type (2020-2025)
5.3 Americas Vaginosis Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaginosis Drug Sales by Region
6.1.1 APAC Vaginosis Drug Sales by Region (2020-2025)
6.1.2 APAC Vaginosis Drug Revenue by Region (2020-2025)
6.2 APAC Vaginosis Drug Sales by Type (2020-2025)
6.3 APAC Vaginosis Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Vaginosis Drug by Country
7.1.1 Europe Vaginosis Drug Sales by Country (2020-2025)
7.1.2 Europe Vaginosis Drug Revenue by Country (2020-2025)
7.2 Europe Vaginosis Drug Sales by Type (2020-2025)
7.3 Europe Vaginosis Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Vaginosis Drug by Country
8.1.1 Middle East & Africa Vaginosis Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Vaginosis Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Vaginosis Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Vaginosis Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaginosis Drug
10.3 Manufacturing Process Analysis of Vaginosis Drug
10.4 Industry Chain Structure of Vaginosis Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaginosis Drug Distributors
11.3 Vaginosis Drug Customer
12 World Forecast Review for Vaginosis Drug by Geographic Region
12.1 Global Vaginosis Drug Market Size Forecast by Region
12.1.1 Global Vaginosis Drug Forecast by Region (2026-2031)
12.1.2 Global Vaginosis Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Vaginosis Drug Forecast by Type (2026-2031)
12.7 Global Vaginosis Drug Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Bayer
13.1.1 Bayer Company Information
13.1.2 Bayer Vaginosis Drug Product Portfolios and Specifications
13.1.3 Bayer Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Bayer Main Business Overview
13.1.5 Bayer Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Vaginosis Drug Product Portfolios and Specifications
13.2.3 Pfizer Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Vaginosis Drug Product Portfolios and Specifications
13.3.3 Sanofi Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Piramal
13.4.1 Piramal Company Information
13.4.2 Piramal Vaginosis Drug Product Portfolios and Specifications
13.4.3 Piramal Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Piramal Main Business Overview
13.4.5 Piramal Latest Developments
13.5 Abbott
13.5.1 Abbott Company Information
13.5.2 Abbott Vaginosis Drug Product Portfolios and Specifications
13.5.3 Abbott Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Abbott Main Business Overview
13.5.5 Abbott Latest Developments
13.6 Galderma
13.6.1 Galderma Company Information
13.6.2 Galderma Vaginosis Drug Product Portfolios and Specifications
13.6.3 Galderma Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Galderma Main Business Overview
13.6.5 Galderma Latest Developments
13.7 Mission
13.7.1 Mission Company Information
13.7.2 Mission Vaginosis Drug Product Portfolios and Specifications
13.7.3 Mission Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Mission Main Business Overview
13.7.5 Mission Latest Developments
13.8 Alkem
13.8.1 Alkem Company Information
13.8.2 Alkem Vaginosis Drug Product Portfolios and Specifications
13.8.3 Alkem Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Alkem Main Business Overview
13.8.5 Alkem Latest Developments
13.9 Xiuzheng
13.9.1 Xiuzheng Company Information
13.9.2 Xiuzheng Vaginosis Drug Product Portfolios and Specifications
13.9.3 Xiuzheng Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Xiuzheng Main Business Overview
13.9.5 Xiuzheng Latest Developments
13.10 Teva
13.10.1 Teva Company Information
13.10.2 Teva Vaginosis Drug Product Portfolios and Specifications
13.10.3 Teva Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Teva Main Business Overview
13.10.5 Teva Latest Developments
13.11 Perrigo
13.11.1 Perrigo Company Information
13.11.2 Perrigo Vaginosis Drug Product Portfolios and Specifications
13.11.3 Perrigo Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Perrigo Main Business Overview
13.11.5 Perrigo Latest Developments
13.12 West-Ward
13.12.1 West-Ward Company Information
13.12.2 West-Ward Vaginosis Drug Product Portfolios and Specifications
13.12.3 West-Ward Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 West-Ward Main Business Overview
13.12.5 West-Ward Latest Developments
13.13 HPGC
13.13.1 HPGC Company Information
13.13.2 HPGC Vaginosis Drug Product Portfolios and Specifications
13.13.3 HPGC Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 HPGC Main Business Overview
13.13.5 HPGC Latest Developments
13.14 Yunnan Baiyao
13.14.1 Yunnan Baiyao Company Information
13.14.2 Yunnan Baiyao Vaginosis Drug Product Portfolios and Specifications
13.14.3 Yunnan Baiyao Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Yunnan Baiyao Main Business Overview
13.14.5 Yunnan Baiyao Latest Developments
13.15 Starpharma
13.15.1 Starpharma Company Information
13.15.2 Starpharma Vaginosis Drug Product Portfolios and Specifications
13.15.3 Starpharma Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Starpharma Main Business Overview
13.15.5 Starpharma Latest Developments
13.16 Novel
13.16.1 Novel Company Information
13.16.2 Novel Vaginosis Drug Product Portfolios and Specifications
13.16.3 Novel Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Novel Main Business Overview
13.16.5 Novel Latest Developments
13.17 Edenvridge
13.17.1 Edenvridge Company Information
13.17.2 Edenvridge Vaginosis Drug Product Portfolios and Specifications
13.17.3 Edenvridge Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Edenvridge Main Business Overview
13.17.5 Edenvridge Latest Developments
14 Research Findings and Conclusion